Top

Published in:

01-08-2012 | Original Article

ERG rearrangement in local recurrences compared to distant metastases of castration-resistant prostate cancer

Authors: Veit J. Scheble, Gregor Scharf, Martin Braun, Christian Ruiz, Susanna Stürm, Karen Petersen, Rudi Beschorner, Alexander Bachmann, Tobias Zellweger, Falko Fend, Glen Kristiansen, Lukas Bubendorf, Nicolas Wernert, David Adler, Sven Perner

Published in: Virchows Archiv | Issue 2/2012

Abstract

Castration-resistant prostate cancer is the second most common cause of cancer death and results in a median survival of less than 2 years. In prostate cancer, fusions between TMPRSS2 and ERG are common. The ERG rearrangement prevalence in local recurrent castration-resistant prostate cancer compared to distant metastatic prostate cancer is unknown. We investigated the frequency of ERG rearrangement in local recurrent castration-resistant prostate cancer compared to distant metastatic prostate cancer, and assessed for associations between androgen receptor (AR) amplification and ERG rearrangement status. Samples from 134 patients diagnosed with prostate cancer (84 local recurrent castration resistant prostate cancer, 55 distant metastatic prostate cancer) were assessed for their ERG rearrangement and AR amplification status by fluorescence in situ hybridization. Statistical analysis was performed using the χ ² test. We found that the ERG rearrangement occurs at a significantly lower frequency in distant metastatic prostate cancer (25 %) than in local recurrent castration-resistant prostate cancer (45 %). The AR amplification frequencies were 45 and 35 % in local recurrent castration-resistant prostate cancer and distant metastatic prostate cancer, respectively. The ERG rearrangement occurred at a lower frequency in distant metastatic prostate cancer compared to local recurrent castration-resistant prostate cancer.

Attard G, Sarker D, Reid A, Molife R, Parker C, de Bono JS (2006) Improving the outcome of patients with castration-resistant prostate cancer through rational drug development. Br J Cancer 95(7):767–774. doi:10.1038/sj.bjc.6603223 CrossRefPubMedPubMedCentral

Appleman LJ (2010) Castration-refractory prostate cancer: new therapies, new questions. Oncology (Williston Park) 24(14):1318–1319, 1326

Mosquera JM, Mehra R, Regan MM, Perner S, Genega EM, Bueti G, Shah RB, Gaston S, Tomlins SA, Wei JT, Kearney MC, Johnson LA, Tang JM, Chinnaiyan AM, Rubin MA, Sanda MG (2009) Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res 15(14):4706–4711. doi:10.1158/1078-0432.CCR-08-2927 CrossRefPubMedPubMedCentral

Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310(5748):644–648. doi:10.1126/science.1117679 CrossRefPubMed

Salami SS, Schmidt F, Laxman B, Regan MM, Rickman DS, Scherr D, Bueti G, Siddiqui J, Tomlins SA, Wei JT, Chinnaiyan AM, Rubin MA, Sanda MG (2011) Combining urinary detection of TMPRSS2: ERG and CaP3 with serum PSA to predict diagnosis of prostate cancer. Urol Oncol. doi:10.1016/j.urolonc.2011.04.001

He H, Magi-Galluzzi C, Li J, Carver P, Falzarano S, Smith K, Rubin MA, Zhou M (2011) The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with “atypical glands suspicious for cancer”. Am J Surg Pathol 35(4):608–614. doi:10.1097/PAS.0b013e31820bcd2d CrossRefPubMed

Rice KR, Chen Y, Ali A, Whitman EJ, Blase A, Ibrahim M, Elsamanoudi S, Brassell S, Furusato B, Stingle N, Sesterhenn IA, Petrovics G, Miick S, Rittenhouse H, Groskopf J, McLeod DG, Srivastava S (2010) Evaluation of the ETS-related gene mRNA in urine for the detection of prostate cancer. Clin Cancer Res 16(5):1572–1576. doi:10.1158/1078-0432.CCR-09-2191 CrossRefPubMed

Scheble VJ, Braun M, Beroukhim R, Mermel CH, Ruiz C, Wilbertz T, Stiedl AC, Petersen K, Reischl M, Kuefer R, Schilling D, Fend F, Kristiansen G, Meyerson M, Rubin MA, Bubendorf L, Perner S (2010) ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol 23(8):1061–1067. doi:10.1038/modpathol.2010.87 CrossRefPubMedPubMedCentral

Braun M, Scheble V, Menon R, Scharf G, Wilbertz T, Petersen K, Beschorner C, Reischl M, Kuefer R, Schilling D, Stenzl A, Kristiansen G, Rubin M, Fend F, Perner S (2011) Relevance of cohort design for studying the frequency of the ERG rearrangement in prostate cancer. Histopathology (in press)

10.

Tomlins SA, Bjartell A, Chinnaiyan AM, Jenster G, Nam RK, Rubin MA, Schalken JA (2009) ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol 56(2):275–286. doi:10.1016/j.eururo.2009.04.036 CrossRefPubMed

11.

Guo CC, Dancer JY, Wang Y, Aparicio A, Navone NM, Troncoso P, Czerniak BA (2011) TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate. Hum Pathol 42(1):11–17. doi:10.1016/j.humpath.2010.05.026 CrossRefPubMed

12.

Scheble VJ, Braun M, Wilbertz T, Stiedl AC, Petersen K, Schilling D, Reischl M, Seitz G, Fend F, Kristiansen G, Perner S (2010) ERG rearrangement in small cell prostatic and lung cancer. Histopathology 56(7):937–943. doi:10.1111/j.1365-2559.2010.03564.x CrossRefPubMed

13.

Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, De Marzo AM, Rubin MA (2007) TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 31(6):882–888. doi:10.1097/01.pas.0000213424.38503.aa00000478-200706000-00008 CrossRefPubMed

14.

Perner S, Svensson MA, Hossain RR, Day JR, Groskopf J, Slaughter RC, Jarleborn AR, Hofer MD, Kuefer R, Demichelis F, Rickman DS, Rubin MA (2010) ERG rearrangement metastasis patterns in locally advanced prostate cancer. Urology 75(4):762–767. doi:10.1016/j.urology.2009.10.010 CrossRefPubMed

15.

Feldman BJ, Feldman D (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1(1):34–45CrossRef

16.

Bubendorf L, Kononen J, Koivisto P, Schraml P, Moch H, Gasser TC, Willi N, Mihatsch MJ, Sauter G, Kallioniemi OP (1999) Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 59(4):803–806PubMed

17.

Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9(4):401–406. doi:10.1038/ng0495-401 CrossRefPubMed

18.

Cai C, Wang H, Xu Y, Chen S, Balk SP (2009) Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer. Cancer Res 69(15):6027–6032. doi:10.1158/0008-5472.CAN-09-0395 CrossRefPubMedPubMedCentral

19.

Han B, Mehra R, Lonigro RJ, Wang L, Suleman K, Menon A, Palanisamy N, Tomlins SA, Chinnaiyan AM, Shah RB (2009) Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol 22(8):1083–1093. doi:10.1038/modpathol.2009.69 CrossRefPubMedPubMedCentral

20.

Leinonen KA, Tolonen TT, Bracken H, Stenman UH, Tammela TL, Saramaki OR, Visakorpi T (2010) Association of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrine-treated prostate cancer. Clin Cancer Res 16(10):2845–2851. doi:10.1158/1078-0432.CCR-09-2505 CrossRefPubMed

21.

Mehra R, Tomlins SA, Yu J, Cao X, Wang L, Menon A, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM (2008) Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res 68(10):3584–3590. doi:10.1158/0008-5472.CAN-07-6154 CrossRefPubMedPubMedCentral

22.

Rickman DS, Chen YB, Banerjee S, Pan Y, Yu J, Vuong T, Perner S, Lafargue CJ, Mertz KD, Setlur SR, Sircar K, Chinnaiyan AM, Bismar TA, Rubin MA, Demichelis F (2010) ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression. Neoplasia 12(12):1031–1040CrossRef

23.

Saramaki OR, Harjula AE, Martikainen PM, Vessella RL, Tammela TL, Visakorpi T (2008) TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res 14(11):3395–3400. doi:10.1158/1078-0432.CCR-07-2051 CrossRefPubMed

24.

Ruiz C, Holz DR, Oeggerli M, Schneider S, Gonzales IM, Kiefer JM, Zellweger T, Bachmann A, Koivisto PA, Helin HJ, Mousses S, Barrett MT, Azorsa DO, Bubendorf L (2011) Amplification and overexpression of vinculin are associated with increased tumour cell proliferation and progression in advanced prostate cancer. J Pathol 223(4):543–552. doi:10.1002/path.2828 CrossRefPubMed

25.

Brown RS, Edwards J, Dogan A, Payne H, Harland SJ, Bartlett JM, Masters JR (2002) Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer. J Pathol 198(2):237–244. doi:10.1002/path.1206 CrossRefPubMed

26.

Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T (2001) Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61(9):3550–3555PubMed

27.

Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, Trapman J, Cleutjens K, Noordzij A, Visakorpi T, Kallioniemi OP (1997) Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 57(2):314–319PubMed

Title: ERG rearrangement in local recurrences compared to distant metastases of castration-resistant prostate cancer
Authors: Veit J. Scheble
Gregor Scharf
Martin Braun
Christian Ruiz
Susanna Stürm
Karen Petersen
Rudi Beschorner
Alexander Bachmann
Tobias Zellweger
Falko Fend
Glen Kristiansen
Lukas Bubendorf
Nicolas Wernert
David Adler
Sven Perner
Publication date: 01-08-2012
Publisher: Springer Berlin Heidelberg
Published in: Virchows Archiv / Issue 2/2012
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-012-1270-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

ERG rearrangement in local recurrences compared to distant metastases of castration-resistant prostate cancer

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2012

PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy

Down-staging (<pT2) of urothelial cancer at cystectomy after the diagnosis of detrusor muscle invasion (pT2) at diagnostic transurethral resection (TUR): is prediction possible?

Stromal p16 expression differentiates endometrial polyp from endometrial hyperplasia

Chondroclasts are mature osteoclasts which are capable of cartilage matrix resorption

Transdifferentiation of pituitary thyrotrophs to lactothyrotrophs in primary hypothyroidism: case report

Training increases concordance in classifying pulmonary adenocarcinomas according to the novel IASLC/ATS/ERS classification